In this issue:
- SLNB for choosing chemotherapy in HR+/HER2– breast cancer with 1–3 positive nodes
- Survival outcomes and care equity in Auckland, NZ
- Women’s responses to breast density information
- Impact of the COVID-19 pandemic on screening and diagnosis
- Outcomes of chemotherapy refusal in older women with high genomic risk ER+ breast cancer
- Trastuzumab deruxtecan vs trastuzumab emtansine in HER2+ mBC
- Neoadjuvant pyrotinib, trastuzumab, docetaxel for HER2+ breast cancer
- Genomics for selecting mBC treatment
- Switching aromatase inhibitor to fulvestrant, + palbociclib, in breast cancer with rising ESR1 mutation
- Trastuzumab deruxtecan in HER2+ breast cancer with brain metastases
Please login below to download this issue (PDF)